163 related articles for article (PubMed ID: 14984974)
21. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype?
Cass I; Holschneider C; Datta N; Barbuto D; Walts AE; Karlan BY
Obstet Gynecol; 2005 Dec; 106(6):1327-34. PubMed ID: 16319259
[TBL] [Abstract][Full Text] [Related]
22. A genetic epidemiological study of carcinoma of the fallopian tube.
Aziz S; Kuperstein G; Rosen B; Cole D; Nedelcu R; McLaughlin J; Narod SA
Gynecol Oncol; 2001 Mar; 80(3):341-5. PubMed ID: 11263928
[TBL] [Abstract][Full Text] [Related]
23. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.
Rabban JT; Krasik E; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Dec; 33(12):1878-85. PubMed ID: 19898224
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Laki F; Kirova YM; This P; Plancher C; Asselain B; Sastre X; Stoppa-Lyonnet D; Salmon R;
Cancer; 2007 May; 109(9):1784-90. PubMed ID: 17351952
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
26. [Carcinoma of the fallopian tube after prophylactic laparoscopic ovariectomy in a patient with a BRCAI mutation].
Dijkhuizen FP; Huisman A; Boonstra H; Aalders AL
Ned Tijdschr Geneeskd; 2003 May; 147(18):877-9. PubMed ID: 12756880
[TBL] [Abstract][Full Text] [Related]
27. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
[TBL] [Abstract][Full Text] [Related]
28. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
Powell CB
Gynecol Oncol; 2006 Jan; 100(1):1-2. PubMed ID: 16368438
[No Abstract] [Full Text] [Related]
29. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
Carcangiu ML; Peissel B; Pasini B; Spatti G; Radice P; Manoukian S
Am J Surg Pathol; 2006 Oct; 30(10):1222-30. PubMed ID: 17001151
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Mahajan NN
Cancer; 2007 Dec; 110(12):2819; author reply 2819-20. PubMed ID: 17969078
[No Abstract] [Full Text] [Related]
31. Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: implications for intraoperative specimen evaluation.
Rabban JT; Mackey A; Powell CB; Crawford B; Zaloudek CJ; Chen LM
Gynecol Oncol; 2011 Jun; 121(3):466-71. PubMed ID: 21353295
[TBL] [Abstract][Full Text] [Related]
32. Occult fallopian tube cancer in a patient with BRCA1 breast cancer.
Brown JV; Epstein HD; Mattison JN; Micha JP; Rettenmaier MA; Goldstein BH
J Minim Invasive Gynecol; 2008; 15(6):749-51. PubMed ID: 18971141
[TBL] [Abstract][Full Text] [Related]
33. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report.
Rose PG; Shrigley R; Wiesner GL
Gynecol Oncol; 2000 May; 77(2):319-20. PubMed ID: 10785486
[TBL] [Abstract][Full Text] [Related]
34. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
Kauff ND; Barakat RR
J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
[TBL] [Abstract][Full Text] [Related]
35. High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy.
Hirst JE; Gard GB; McIllroy K; Nevell D; Field M
Int J Gynecol Cancer; 2009 Jul; 19(5):826-9. PubMed ID: 19574767
[TBL] [Abstract][Full Text] [Related]
36. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation.
Finch A; Metcalfe KA; Chiang J; Elit L; McLaughlin J; Springate C; Esplen MJ; Demsky R; Murphy J; Rosen B; Narod SA
Psychooncology; 2013 Jan; 22(1):212-9. PubMed ID: 21913283
[TBL] [Abstract][Full Text] [Related]
37. Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
Mingels MJ; Roelofsen T; van der Laak JA; de Hullu JA; van Ham MA; Massuger LF; Bulten J; Bol M
Gynecol Oncol; 2012 Oct; 127(1):88-93. PubMed ID: 22710074
[TBL] [Abstract][Full Text] [Related]
38. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.
Vicus D; Shaw PA; Finch A; Rosen B; Murphy J; Armel S; Sun P; Narod SA
Gynecol Oncol; 2010 Sep; 118(3):295-8. PubMed ID: 20722102
[TBL] [Abstract][Full Text] [Related]
40. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review.
Finch A; Narod SA
Maturitas; 2011 Nov; 70(3):261-5. PubMed ID: 21893388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]